All News
Is Rituximab and Belimumab the Combination to Beat Lupus?
On day 2 of EULAR conference, Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. B cell depletion with rituximab is common treatment for refractory SLE, though real-world data for rituximab has been uncertain. It is known that B-cell activating factor (BAFF) levels can increase after rituximab, which can lead to disease flares. Using belimumab, a human monoclonal antibody inhibiting BAFF, could be a potential therapeutic option after rituximab infusions.
Read Article
SLE Molecular Phenotype for Personalized Medicine: Drs. Yusof and Garantziotis #EULAR2021
https://t.co/HJzyXBJ0fZ https://t.co/06jvGcczmi
Links:
Dr. John Cush RheumNow ( View Tweet)
Would it help to record #SLE BILAG-2004 index in your busy clinic if this was made easy? Dr Carter reformatted EASY-BILAG with colour-coding and in-built glossary. Most assessment can be done in 1 page!This tool boosts accuracy, speed & usability #EULAR2021 #POS0748 @RheumNow https://t.co/v27rrK0ob3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Would you use #Telemedicine (TM) to follow-up #SLE patients post #COVID? Dr So showed in an RCT (N=122),patient satisfaction and time-to-review were better in TM vs Face-to-Face. Although none had COVID, >pts in TM were hospitalised and trend to⬆️FU #EULAR2021 #POS1164 @RheumNow https://t.co/p7aWv4AVm7
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
@almirall_m I don't monitor routinely. High rate of seroconversion post-TNFi but only small cases of TNFi-induced SLE (mild mostly). To screen with ANA if develop SLE features
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Due to significant interest in our Tweet about #POS0204 #EULAR2021, let's vote. Would you monitor #ANA in patients receiving therapy with #TNF inhibitors?🧐@RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2021 POS0105: Predictors of flare in SLE low disease activity state:
⭐️Ongoing glucocorticoid treatment
⭐️Ongoing immunosuppressant treatment
⭐️Anti-RNP antibody
@RheumNow
Eric Dein ejdein1 ( View Tweet)
How to Measure Success in Lupus? Dr. Kathryn Dao ( @KDAO2011 )
https://t.co/z8c8moIQCa
#EULAR2021
Links:
Dr. John Cush RheumNow ( View Tweet)
We need to look after #mentalhealth (MH) of #SLE patients.Dr Petri studied large US database. MH prevalence = 36%(SLE) and 29%(Nephritis;LN).LN with MH stayed 7.2 days longer in-patient vs without MH. Health cost/year⬆️in SLE+MH ($49,553 vs $26,064) #EULAR2021 #POS0304 @RheumNow https://t.co/wa7XmJxx9O
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson
Dr. Yusof interviews Dr. Robinson about abstract OP0013 presented at the virtual #EULAR2021 meeting.
https://t.co/IPe6lMM7NQ https://t.co/Dt36N3OhZg
Links:
Dr. John Cush RheumNow ( View Tweet)
Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021
On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab.
https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021. OP0293: Best disease activity measure for SLE flares?
⭐️c-SFI and SLE-DAS had best performance
⭐️SLE-DAS: easy to use for daily practice
@RheumNow https://t.co/9LJfbYxqOs
Eric Dein ejdein1 ( View Tweet)
BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares https://t.co/dUJMKFkZ52 https://t.co/oAgKcGbW0k
Andy Vermaut AndyVermaut ( View Tweet)
#Eular2021 OP0289:
⭐️Remission off-Rx: SLEDAI=0 (minus serol), no IS
⭐️Remission on-Rx: SLEDAI 0, Pred<5mg, maintenance IS
⭐️LDAS: SLEDAI<=2 wo pred or IS
⭐️LLDAS: SLEDAI <=4, no maj organ, no new features, pred <=7.5+main
These states have ⬇️ damage accrual, rec'd T2T
@Rhuemnow
Eric Dein ejdein1 ( View Tweet)
How Do You Measure Success When It Comes to SLE? by Dr. Kathryn Dao ( @KDAO2011 ) #EULAR2021
https://t.co/aVKY4B9CfW https://t.co/ffruCDouaE
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 Complex Immune Disturbances in ANA+ Individuals: Drs. Yusof and Hassan
https://t.co/nvSU7ArEUU https://t.co/7pJ5ypqDJn
Links:
Dr. John Cush RheumNow ( View Tweet)
Check out our Lupus content from #EULAR2021 at RheumNow.
https://t.co/Gmh4sFv4Jl https://t.co/yBkbeMn0Yd
Links:
Dr. John Cush RheumNow ( View Tweet)
Does skin #lupus respond differently to rituximab?Dr Carter @LucyCarter6 reported 75% cutaneous response rate but overall non-response to tx was caused by skin domain. Interestingly, resistant skin post-tx was associated with low baseline #IFN scores #EULAR2021 #OP0134 @RheumNow https://t.co/JdtwdwNR4Z
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
AVN in SLE is ⬇️ing over time! risks are same: younger, male, glucocorticoids & also found hyperlipidemia. ?due to older age of onset & less steroids over time & better immune suppressants POS0730 @RheumNow #EULAR2021 @eular_org https://t.co/IG3NVrZl4D
Janet Pope Janetbirdope ( View Tweet)
Once approved, what type of patients with #SLE would you treat with #anifrolumab? #EULAR2021 #OP0131 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
